UnitedHealth Group, the largest health insurer in the United States, has been attempting to arrange meetings with President Donald Trump, though no formal sit-down has yet been confirmed, according to a report from The Wall Street Journal. These outreach efforts are part of an intensified lobbying campaign by the company as it navigates mounting regulatory scrutiny, soaring operational costs, and a steep decline in its stock value.
The company has been under pressure in recent months as federal authorities pursue multiple investigations, including a criminal probe into its Medicare billing practices. These challenges have rattled investors, driving UnitedHealth’s share price down by nearly 30 percent this year. In response, Stephen Hemsley, who returned to the CEO role in May after the abrupt removal of Andrew Witty, has pledged to restore confidence in the firm by stabilizing operations and rebuilding trust with stakeholders.
While UnitedHealth has not yet secured a direct meeting with President Trump, Hemsley has met with key figures in the administration. According to officials, he recently held talks with Susie Wiles, Trump’s chief of staff, although the ongoing criminal investigation into the company was not mentioned during their discussion. Instead, the conversation reportedly centered on the Medicare program, which provides coverage for seniors and disabled Americans, as well as related policy issues that affect the private insurance sector.
Hemsley also engaged with Chris Klomp, the federal official in charge of Medicare, over dinner earlier this summer. Their discussion touched on billing practices for Medicare Advantage plans and the supplemental benefits offered to enrollees through private insurers. These conversations highlight the strategic importance UnitedHealth places on influencing the direction of Medicare policy at a time when government oversight of the industry is intensifying.
In a statement responding to Reuters, UnitedHealth underscored that health policy decisions have far-reaching implications across the country. The company emphasized that it has a responsibility to collaborate with both the administration and Congress to ensure better affordability and access to care for patients. It argued that such engagement is especially crucial now, as pivotal decisions about the future of healthcare are being made in Washington.
The White House, for its part, has downplayed any suggestion of favoritism. Spokesperson Kush Desai told the Wall Street Journal that the Trump administration regularly meets with insurance providers as part of its broader effort to fulfill the President’s promise of lowering healthcare costs and improving services for Americans. The administration’s position reflects a routine practice of consulting with major stakeholders in the industry, though the timing of UnitedHealth’s outreach has drawn attention, given the company’s ongoing legal and financial challenges.
For UnitedHealth, securing face time with President Trump could prove significant as it seeks to shape policy debates and address the growing pressures on its Medicare business. At the same time, the company must tread carefully in balancing its lobbying efforts with the realities of federal investigations that have already cast a long shadow over its operations.
